By: Daniel Aruch, MD, oncologist at Virginia Oncology Associates
It’s an exciting time for oncologists as numerous advances in immunotherapy allow us to offer more treatment options and greater hope to our patients. In the treatment of advanced blood cancers, chimeric antigen receptor (CAR) T-cell therapy is offering meaningful, long-lasting results. CAR T-cell therapy is currently approved in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
